PDCD1 and cancer: While FDA-approved for use in various solid and hematologic malignancies, most commonly cutaneous melanoma and non-small cell lung cancer (9), efficacy is not universal and ICI-ICI combination therapy (anti-CTLA-4 plus anti-PD-1) as well as ICI-chemotherapy or ICI-radiation treatment have emerged as potential solutions (10).